17
Participants
Start Date
January 31, 2014
Primary Completion Date
December 31, 2015
Study Completion Date
December 31, 2015
TPI 287
TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
Bevacizumab
Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
University of Rochester Medical Center, Rochester
University of Virginia Health System, Charlottesville
H Lee Moffitt Cancer Center and Research Institute, Inc., Tampa
University of Alabama at Birmingham, Birmingham
The Ohio State University Wexner Medical Center, Columbus
Northwestern Medical Faculty Foundation, Chicago
Washington University, School of Medicine, St Louis
Memorial Hermann Hospital, Houston
Swedish Neuroscience Institute, Seattle
Dartmouth-Hitchcock Medical Center, Lebanon
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
Lead Sponsor
Cortice Biosciences, Inc.
INDUSTRY